Exhibit 99.1

First Titan Corp. Acquiring AngioSoma, Inc.

Houston, Texas (June 7, 2016) – First Titan Corp. (OTCQB: FTTN) (the “Company”) is proud to announce the acquisition of AngioSoma, Inc., effective ten (10) days after the filing of a Form 14F with the SEC.  The acquisition of AngioSoma, Inc.  as a subsidiary of the Company provides diversification outside of the depressed oil & gas industry and significant upside potential with the intellectual property licensed by AngioSoma, Inc.

On June 3, 2016, the Company entered into an Agreement and Plan of Reorganization (the “Agreement”) with AngioSoma Research, Inc., a Texas corporation, a newly formed wholly owned subsidiary of the Company, AngioSoma, Inc., a Nevada corporation, and the stockholders of AngioSoma, Inc.  Pursuant to the Agreement, AngioSoma Research, Inc. will merge with and into AngioSoma, Inc., and the Company’s name will change to AngioSoma, Inc. The surviving corporation, AngioSoma Research, Inc., will be domiciled in Texas as a wholly owned subsidiary of the Company under its new name AngioSoma, Inc. The purchase price for the acquisition consists of the issuance by the Company of 20,000,000 shares of our Common Stock, par value $0.001 per share to the stockholders of AngioSoma, Inc.

Further information is available on Forms 8K and 14F filed with the US Security and Exchange Commission, available at http://www.sec.gov.

ABOUT FIRST TITAN CORP.

First Titan Corp. (http://www.firsttitanenergy.com), through its wholly owned subsidiary, First Titan Energy, LLC, is committed to the exploration and development of oil and natural gas resources around the globe. The Company continually seeks to partner with energy developers that are pursuing innovative new methods of oil and gas extraction, including the development of new technologies, cleaner methods and unconventional resources.

ABOUT ANGIOSOMA, INC.

AngioSoma, Inc. (http://www.angiosoma.com), a Texas corporation based in Montgomery, Texas, acquired the rights to Liprostin™, a Peripheral Artery Disease therapy using FDA approved Alprostadil™ packaged inside a proprietary Liposome for controlled drug release.  Phase II Clinical Trials (a-b-c) had been completed with excellent results treating intermittent claudication (pain from walking) and non-healing ulceration.  Data shows Liprostin™ is more than twice as effective as and four times faster than FDA approved drug Cilostazol™ for treating intermittent claudication.  A huge, non-healing ulceration was eliminated in 200 days. We have established our protocols and are ready to retain a Contract Research Organization to conduct Clinical Trials Phase III with the 60 patient protocol approved by the FDA, which will take approximately 12 months to complete.